Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Fig. 2

pCR by PAM50 breast cancer subtype and hormone receptor status. aOther subtypes combined included the luminal A, luminal B, and basal-like subtypes. CI confidence interval, HER2 human epidermal growth factor receptor 2, PAM50 Prediction Analysis of Microarray with the 50-gene classifier, pCR pathologic complete response, TCH + P docetaxel, carboplatin, and trastuzumab plus pertuzumab, T-DM1 + P trastuzumab emtansine plus pertuzumab

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us